To include your compound in the COVID-19 Resource Center, submit it here.

Chromatin remodeling gains traction with Merck-Foghorn partnership

Plus Merck, Zymeworks deal to develop multispecific antibodies

Merck’s Wednesday deal with Foghorn is the latest signal that chromatin remodeling is gaining traction.

Under the deal, Merck & Co. Inc. (NYSE:MRK) will have exclusive, global rights to cancer

Read the full 294 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers